LivaNova PLC (LIVN) exhibits 67.7% gross margins and 17.3% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 15.6x enterprise multiple and 4.8% implied options volatility.
Sustained 67.7% gross profitability converts into 14.4% operating margin and 17.3% ROIC, outpacing sector cost of capital.
ROIC: 17.3% // GM: 67.7%YoY revenue trajectory of +10.7% paired with 3.87% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +10.7% // FCF YLD: 3.87%Altman Z-Score of 2.21 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.21 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 15.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $81.25 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend -17.5% net margins.
NET MARGIN: -17.5% // D/E: 0.29x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for LIVN & activate live FRED threshold breach alerts.